These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 30309218)

  • 1. Prevalence of PALB2 Germline Mutations in Early-onset and Familial Breast/Ovarian Cancer Patients from Pakistan.
    Rashid MU; Khan FA; Muhammad N; Loya A; Hamann U
    Cancer Res Treat; 2019 Jul; 51(3):992-1000. PubMed ID: 30309218
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Constitutional CHEK2 mutations are infrequent in early-onset and familial breast/ovarian cancer patients from Pakistan.
    Rashid MU; Muhammad N; Faisal S; Amin A; Hamann U
    BMC Cancer; 2013 Jun; 13():312. PubMed ID: 23806170
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
    Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
    Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutation status of RAD51C, PALB2 and BRIP1 in 100 Japanese familial breast cancer cases without BRCA1 and BRCA2 mutations.
    Sato K; Koyasu M; Nomura S; Sato Y; Kita M; Ashihara Y; Adachi Y; Ohno S; Iwase T; Kitagawa D; Nakashima E; Yoshida R; Miki Y; Arai M
    Cancer Sci; 2017 Nov; 108(11):2287-2294. PubMed ID: 28796317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathogenic and likely pathogenic variants in PALB2, CHEK2, and other known breast cancer susceptibility genes among 1054 BRCA-negative Hispanics with breast cancer.
    Weitzel JN; Neuhausen SL; Adamson A; Tao S; Ricker C; Maoz A; Rosenblatt M; Nehoray B; Sand S; Steele L; Unzeitig G; Feldman N; Blanco AM; Hu D; Huntsman S; Castillo D; Haiman C; Slavin T; Ziv E
    Cancer; 2019 Aug; 125(16):2829-2836. PubMed ID: 31206626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PALB2 mutations in BRCA1/2-mutation negative breast and ovarian cancer patients from Poland.
    Kluska A; Balabas A; Piatkowska M; Czarny K; Paczkowska K; Nowakowska D; Mikula M; Ostrowski J
    BMC Med Genomics; 2017 Mar; 10(1):14. PubMed ID: 28279176
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Germline mutations of PALB2 gene in a sequential series of Chinese patients with breast cancer.
    Zhang K; Zhou J; Zhu X; Luo M; Xu C; Yu J; Deng M; Zheng S; Chen Y
    Breast Cancer Res Treat; 2017 Dec; 166(3):865-873. PubMed ID: 28825143
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathologic findings in breast, fallopian tube, and ovary specimens in non-BRCA hereditary breast and/or ovarian cancer syndromes: a study of 18 patients with deleterious germline mutations in RAD51C, BARD1, BRIP1, PALB2, MUTYH, or CHEK2.
    Schoolmeester JK; Moyer AM; Goodenberger ML; Keeney GL; Carter JM; Bakkum-Gamez JN
    Hum Pathol; 2017 Dec; 70():14-26. PubMed ID: 28709830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel germline PALB2 deletion in Polish breast and ovarian cancer patients.
    Dansonka-Mieszkowska A; Kluska A; Moes J; Dabrowska M; Nowakowska D; Niwinska A; Derlatka P; Cendrowski K; Kupryjanczyk J
    BMC Med Genet; 2010 Feb; 11():20. PubMed ID: 20122277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spectrum of PALB2 germline mutations and characteristics of PALB2-related breast cancer: Screening of 16,501 unselected patients with breast cancer and 5890 controls by next-generation sequencing.
    Zhou J; Wang H; Fu F; Li Z; Feng Q; Wu W; Liu Y; Wang C; Chen Y
    Cancer; 2020 Jul; 126(14):3202-3208. PubMed ID: 32339256
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence of BRCA1 and BRCA2 mutations in Pakistani breast and ovarian cancer patients.
    Rashid MU; Zaidi A; Torres D; Sultan F; Benner A; Naqvi B; Shakoori AR; Seidel-Renkert A; Farooq H; Narod S; Amin A; Hamann U
    Int J Cancer; 2006 Dec; 119(12):2832-9. PubMed ID: 16998791
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deleterious RAD51C germline mutations rarely predispose to breast and ovarian cancer in Pakistan.
    Rashid MU; Muhammad N; Faisal S; Amin A; Hamann U
    Breast Cancer Res Treat; 2014 Jun; 145(3):775-84. PubMed ID: 24800917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutation analysis of PALB2 gene in French breast cancer families.
    Damiola F; Schultz I; Barjhoux L; Sornin V; Dondon MG; Eon-Marchais S; Marcou M; ; Caron O; Gauthier-Villars M; de Pauw A; Luporsi E; Berthet P; Delnatte C; Bonadona V; Maugard C; Pujol P; Lasset C; Longy M; Bignon YJ; Fricker JP; Andrieu N; Sinilnikova OM; Stoppa-Lyonnet D; Mazoyer S; Muller D
    Breast Cancer Res Treat; 2015 Dec; 154(3):463-71. PubMed ID: 26564480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Spectrum and characteristics of germline PALB2 pathogenic variants in 1556 early-onset breast cancer patients in China.
    Li J; He P; Cai Q; Chen L; Wang Y; Cai W; Qiu Y; Liu S; Guo W; Chen M; Lin Y; Wang C; Fu F
    J Cancer Res Clin Oncol; 2024 Jun; 150(6):322. PubMed ID: 38914840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of FANCM germline variants in BRCA1/2 negative breast and/or ovarian cancer patients from Pakistan.
    Rashid MU; Muhammad N; Shehzad U; Khan FA; Loya A; Hamann U
    Fam Cancer; 2023 Jan; 22(1):31-41. PubMed ID: 35802266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A PALB2 truncating mutation: Implication in cancer prevention and therapy of Hereditary Breast and Ovarian Cancer.
    Velázquez C; Esteban-Cardeñosa EM; Lastra E; Abella LE; de la Cruz V; Lobatón CD; Durán M; Infante M
    Breast; 2019 Feb; 43():91-96. PubMed ID: 30521987
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contribution of inherited mutations in the BRCA2-interacting protein PALB2 to familial breast cancer.
    Casadei S; Norquist BM; Walsh T; Stray S; Mandell JB; Lee MK; Stamatoyannopoulos JA; King MC
    Cancer Res; 2011 Mar; 71(6):2222-9. PubMed ID: 21285249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frequency of pathogenic germline mutation in CHEK2, PALB2, MRE11, and RAD50 in patients at high risk for hereditary breast cancer.
    Kim H; Cho DY; Choi DH; Oh M; Shin I; Park W; Huh SJ; Nam SJ; Lee JE; Kim SW
    Breast Cancer Res Treat; 2017 Jan; 161(1):95-102. PubMed ID: 27783279
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene panel sequencing in familial breast/ovarian cancer patients identifies multiple novel mutations also in genes others than BRCA1/2.
    Kraus C; Hoyer J; Vasileiou G; Wunderle M; Lux MP; Fasching PA; Krumbiegel M; Uebe S; Reuter M; Beckmann MW; Reis A
    Int J Cancer; 2017 Jan; 140(1):95-102. PubMed ID: 27616075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contribution of BRCA1 large genomic rearrangements to early-onset and familial breast/ovarian cancer in Pakistan.
    Rashid MU; Muhammad N; Amin A; Loya A; Hamann U
    Breast Cancer Res Treat; 2017 Jan; 161(2):191-201. PubMed ID: 27826754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.